179 related articles for article (PubMed ID: 28541985)
1. New Injectable Drug Treats Moderate-To-Severe Plaque Psoriasis.
Aschenbrenner DS
Am J Nurs; 2017 Jun; 117(6):23. PubMed ID: 28541985
[No Abstract] [Full Text] [Related]
2. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
Tong Y; Peranteau AJ; Nawas Z; Tyring SK
Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
[TBL] [Abstract][Full Text] [Related]
3. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
6. Treatment of inverse psoriasis with efalizumab.
George D; Rosen T
J Drugs Dermatol; 2009 Jan; 8(1):74-6. PubMed ID: 19180901
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
Blauvelt A; Reich K; Warren RB; Szepietowski JC; Sigurgeirsson B; Tyring SK; Messina I; Bhosekar V; Oliver J; Papavassilis C; Frueh J; Langley RGB
Br J Dermatol; 2017 Sep; 177(3):879-881. PubMed ID: 28498514
[No Abstract] [Full Text] [Related]
8. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
Rallis E; Verros CD
Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
[No Abstract] [Full Text] [Related]
9. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
Gisondi P; Giglio MD; Girolomoni G
J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
[TBL] [Abstract][Full Text] [Related]
10. Extensive plaque psoriasis successfully treated with adalimumab (Humira).
Sladden MJ; Mortimer NJ; Hutchinson PE
Br J Dermatol; 2005 May; 152(5):1091-2. PubMed ID: 15888191
[No Abstract] [Full Text] [Related]
11. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
12. Briakinumab for the treatment of plaque psoriasis.
Traczewski P; Rudnicka L
BioDrugs; 2012 Feb; 26(1):9-20. PubMed ID: 22077474
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
Sobell JM; Hallas SJ
Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of extensive plaque psoriasis--regulation, cost and reimbursement.
Rabinovich M; Fainaru M
Isr Med Assoc J; 2003 Nov; 5(11):817-8. PubMed ID: 14650110
[No Abstract] [Full Text] [Related]
16. Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report.
Odorici G; Losi A; Ciardo S; Pellacani G; Conti A
Skin Res Technol; 2018 Feb; 24(1):160-162. PubMed ID: 29067742
[No Abstract] [Full Text] [Related]
17. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
Campa M; Menter A
Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
19. Response of severe psoriasis to infliximab.
Mang R; Stege H; Ruzicka T; Krutmann J
Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
[No Abstract] [Full Text] [Related]
20. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
